Kornimate/medical-research-clean huggingface dataset:
assessment of non-invasive tools for detecting active inflammatory bowel disease

Conditions: Inflammatory Bowel Disease (IBD); Crohn Disease (CD); Ulcerative Colitis (UC)

Summary: part of the success of the treatment of people living with inflammatory bowel diseases (ibd) depends on the information that the doctor can obtain from the different clinical tests. some of these tests are invasive such as the colonoscopy but other such the fecal calprotectin test, which measures intestinal inflammation, are non-invasive and useful to evaluate the success of the treatments. unfortunately, the results from the non-invasive tests are not always clear and need to be complete with invasive tests for the right diagnosis. the aim of this research is to test new stool markers for assisting the gastroenterologist to diagnose inflammatory bowel conditions including crohn's disease (cd) and ulcerative colitis (uc) and to carefully monitoring the effects of medications on remission. we are using applications based on the use of mass spectrometry for identifying the proteins that are released by the host in the stools. we have identified more than 400 proteins in total. based on informatics, we have been able to produce lists of unique stool proteins that can rapidly inform the doctor if the person has an ibd, whether it is a cd or an uc and, more importantly for the treatment, if the ibd is active or in remission. the purpose of this study is to validate these protein markers in a blind test, where the real diagnosis will only be revealed after the analysis of the samples. this study will bring a new power tool to assist the gastroenterologist in the treatment of people living with ibd.


Eligibility criteria:
inclusion criteria: * be affected with one of the two main inflammatory bowel diseases (crohn's disease of ulcerative colitis). * be invited to participate on the base of a routine follow up by their gastroenterologist. * be scheduled for a calprotectin test and a colonoscopy. * accept to participate and provide an extra stool sample for analysis. exclusion criteria: * having no history of inflammatory bowel disease. * be affected with an history of gastrointestinal disease other than crohn disease or ulcerative colitis.

Keywords: diagnosis non-invasive remission
mibg scintigraphy and strain echocardiography in the detection of subclinical cardiovascular effects one year after (neo)adjuvant breast cancer treatment with docetaxel, doxorubicin and cyclophosphamide (tac): a pilot study

Conditions: Breast Cancer

Summary: many patients with breastcancer in the past, were treated with tac. these last years, there is more and more focus on the effects of chemotherapy, particularly in children treated with this. one of these effects is damage to the heart muscle, which ultimately might affect the pump-function of the heart . in adults, the effect of treatment with tac on the heart, has not been previously investigated. the possibility exists that the adverse reactions in children are found in adults also could occur. therefore we have initiated this trial.

given the lack of data on the incidence of subclinical cardiotoxicity after treatment with tac we want to assess whether subclinical cardiovascular damage is present in adult patients with breast cancer who have completed treatment with (neo)adjuvant tac one year previously, using mibg (meta-iodobenzylguanidine) scintigraphy, novel echocardiographic techniques and blood biomarkers. following the study by lipshultz et al. we expect to find at least in 25% of the patients signs of subclinical cardiovascular damage with at least one of the three techniques.(11) if at least 10% is observed we will conclude that it is useful to further pursue the use of these techniques for the detection of subclinical cardiotoxicity in a next clinical study which will be powered to assess the predictive value of these techniques for the development of clinical heart failure. if a lower percentage is observed we will conclude that it is not useful to further pursue the use of these techniques for the detection of subclinical cardiotoxicity.

Eligibility criteria:
inclusion criteria: * female patients with breast cancer, ≥ 18 years old at the time of breast cancer diagnosis * (neo)adjuvant treatment with docetaxel, doxorubicin and cyclophosphamide (tac) completed one year before inclusion exclusion criteria: * evidence of breast cancer recurrence or metastatic disease * evidence of heart disease at the time of breast cancer diagnosis * evidence of renal failure at the time of cardiac evaluation * pregnant or lactating * participation in a research protocol with ionizing radiation within one year before inclusion. * evidence of diabetes mellitus or parkinson's disease * evidence of an mibg-accumulating tumor (pheochromocytoma, paraganglioma, chemodectoma, ganglioneuroma, neuroblastoma, carcinoid, medullary thyroid cancer, neurofibromatosis, retinoblastoma, esthesioneuroma, schwannoma, merkelcel-tumor, pancreatic islet cell tumors, small cell lung carcinoma, melanoma

Keywords: cardiotoxicity breast cancer treatment mibg scintigraphy strain echocardiography patients who have been treated with tac one year previously
the effect of schroth exercises on cerebral cortical thickness and motor and proprioceptive fibres

Conditions: Adolescent Idiopathic Scoliosis

Summary: adolescent idiopathic scoliosis (ais): it is a type of structural scoliosis of unknown aetiology and most commonly seen in girls aged 10-18 years. in addition to spinal deformity, postural asymmetry, proprioceptive sensory, vestibular and vestibulospinal system dysfunctions may be observed in ais. the schroth method is a scoliosis-specific exercise approach that uses postural, scoliosis-specific sensorimotor and breathing exercises and is widely used in scoliosis rehabilitation. the treatment programme consists of correction of scoliotic posture with the help of exteroceptive and proprioceptive stimulation and mirrors, isometrics and other exercises to lengthen or strengthen asymmetric muscles, and maintaining a specific breathing pattern. several studies have shown that the schroth method improves cobb angles, slows curve progression, reduces the need for surgery, increases back muscle strength and improves respiratory function. however, although the schroth method is widely used in ais rehabilitation, no study has investigated the effects of schroth exercises on cerebral cortical thickness, proprioceptive sensation and corticospinal pathways. the aim of this study was to compare the effects of schroth and traditional exercises on cortical thickness, proprioceptive sensation and corticospinal tracts in individuals with ais.


Eligibility criteria:
inclusion criteria: * being a female individual between the ages of 10-18 * being diagnosed with ais * cobb angle should be maximum 25º * all participants do not have any disease that affects the nervous system. * all participants must use their right hand as the dominant hand * all participants do not have any chronic disease requiring the use of any neurological or psychiatric medication. * permission to participate in the study is given by the parents of all participants. exclusion criteria: * mri of individuals who do not have any mental problems, neurological, psychiatric, muscular, rheumatic or orthopedic diseases will be included in the study.
assessment of biomarkers in patients with decompensated heart failure and underlying coronary artery disease

Conditions: Heart Failure With Reduced Ejection Fraction; Coronary Artery Disease

Summary: assessment of biomarkers in patients with decompensated heart failure and underlying coronary artery disease

this is a cross-sectional, single center exploratory study of plasma biomarker levels in adults with decompensated heart failure and significant underlying coronary artery disease as compared with age-matched healthy controls. subjects will not receive a therapeutic treatment as part of this study and will undergo a single blood draw.

Eligibility criteria:
inclusion criteria: group 1: heart failure with coronary artery disease subjects * symptomatic heart failure (≥ 3 months) with most recently documented lvef ≤ 40% (echo must have been completed in last 12 months prior to enrollment.) * significant underlying coronary artery disease as evidenced by: * previous myocardial infarction * prior coronary artery bypass graft * 50% coronary stenosis of one or more arteries and/or * history of percutaneous coronary intervention with or without stenting * age 18 years or older at the first screening visit group 2: healthy subjects • age 18 years or older at the first screening visit and within 20% of mean age of group 1 subjects exclusion criteria: group 1: * documented history of "severe" valvular disease * documented history of atrial fibrillation, ventricular fibrillation or ventricular tachycardia. * recent or current use of anticoagulant medications such as fxa inhibitors, direct thrombin inhibitors, vitamin k antagonists, or heparin. (within 1 month of screening) group 2: * known significant cardiovascular or hematological condition * recent or current use of anticoagulant medications such as fxa inhibitors, direct thrombin inhibitors, vitamin k antagonists, or heparin. (within 1 month of screening) * recent cold or flu symptoms, respiratory infection or surgery (within 2 weeks of screening) * history of asthma * history of peptic ulcers
the impact of early follow-up on readmission rates in ami patients

Conditions: Myocardial Infarction

Summary: with no prior prospective study to demonstrate the benefit of an early post-discharge follow-up appointment in reducing readmission rates in the post-myocardial infarction (mi patient population, we propose to conduct the first randomized, prospective trial to better elucidate the association between early and standard follow-up on readmission rates. the investigators hypothesize that unlike heart failure or advanced valvular disease patients, the benefit of early outpatient follow-up in reducing readmission of post-mi patients will be less clear. thus, the investigators primary aim will be to determine the effect of early outpatient follow-up post-discharge on 90 day all-cause readmission rates (exclusive of planned readmissions known at the time of discharge). secondary aims are to describe 1) causes of readmissions within 90 days, 2) any cardiovascular-related complications and any deaths that occur from discharge through 90 days, 3) 30-day readmission rates and 4) median time to readmission among those readmitted. finally, the investigators will examine the distribution of demographic, clinical and socioeconomic characteristic according to readmission vs. no readmission. the investigators do not expect to have sufficient endpoints for full predictive modeling, but believe this exploratory work will provide a foundation for future studies. the investigators postulate that the design and methodology of our current study could be used to answer similar questions in other subsets of patients.


Eligibility criteria:
inclusion criteria: * patients with acute mi (stemi or nstemi) will be recruited from the pac-ccu service and may have been admitted through the duke emergency department or transferred from a referring hospital. - clinical events and treatment during the hospitalization (e.g., medical management versus cardiac catheterization, icu vs. non-icu care, choice of medications, etc.) will not influence inclusion in the trial and inclusion in the trial will not influence treatment during hospitalization or during follow up, except for the timing of the follow-up appointment. exclusion criteria: * patients treated with coronary artery bypass grafting will be excluded for the purposes of this trial to avoid conflicts with usual post-operative management. * additionally, patients with features or clinical courses that would preclude the possibility of readmission will be excluded. * examples include transition of care goals to comfort care, transition of care to inpatient or outpatient hospice, or the development of complications during the hospitalization that require early follow up appointments (e.g., diagnosis of malignancy). * patients discharged to skilled nursing facilities will be eligible for this study.
use of topical budesonide in the treatment of eosinophilic esophagitis

Conditions: Eosinophilic Esophagitis

Summary: this study is designed to evaluate whether or not oral viscous budesonide is effective in treating children with eosinophilic esophagitis.


Eligibility criteria:
inclusion criteria: * histologic evidence of ee defined as greater than 20 eosinophils per hpf on esophageal biopsy * ages 1 yrs and older * ability to continue the same diet that the patient was on at the time of egd with biopsy exclusion criteria: * adverse reaction or allergy to budesonide * pregnancy * chronic diseases requiring immunomodulatory therapy * use of swallowed topical corticosteroids for ee within the past 3 months * use of systemic steroids 2 months prior to study entry * upper gastrointestinal bleed within 4 months of study entry * chronic use of medications that predispose to upper gastrointestinal bleeding including non-steroidal anti-inflammatory medications or anticoagulants * evidence of adrenal suppression prior to study entry * evidence of concurrent eosinophilic gastritis, enteritis, colitis, or proctitis * recent changes in asthma or allergic rhinitis therapy for 3 months

Keywords: eosinophils esophagitis microscopy
bone mass changes in anorexia nervosa patient followed during 4 years

Conditions: Anorexia Nervosa; Osteoporosis

Summary: the mechanism of bone loss in anorexia nervosa is complex. marrow adipose tissue seems to play a role in the regulation of bone metabolism. adipocytes secrete cytokines and adipokines that either stimulate or inhibit adjacent osteoblasts. this study consist to explore the relationship in anorexia nervosa patients with change in bone mineral density and adipokines like leptin, adiponectin and préf-1 bone mineral densities will be measure in 180 anorexia nervosa patients at inclusion and every two years during 6 years.it is assessed blood and urinary calcium and phosphate levels, bone remodelling markers and adipokines (leptin, adiponectin and préf-1)


Eligibility criteria:
inclusion criteria: * anorexia patient defined by dsm iv diagnostic criteria exclusion criteria: * patient with other psychiatric disease * patient with other a metabolic bone disease

Keywords: adiponectin bone remodelling markers
effects of vital shower on quality of life, immune function, cardiovascular regulation and well-being

Conditions: General Population

Summary: the aim of this exploratory randomized controlled clinical study is to evaluate the health-promoting effects of kneipp hydrotherapy, in the form of the vital shower in a four-week daily application.


Eligibility criteria:
inclusion criteria: * female and male patients between 18 and 70 years of age exclusion criteria: * bad general condition * serious acute or chronic comorbidity * pregnancy and breast feeding period/ in the next 6 months * participation in a clinical trial within the last 3 months before enrollment * simultaneous participation in another clinical trial * raynaud's disease or cold agglutinin disease * severe mental illness * insufficiently treated dermatological diseases (e.g. neurodermatitis, psoriasis) * non-compatible sanitary shower or bath devices
a study of lcar-aio in subjects with relapsed/refractory systemic lupus erythematosus

Conditions: Systemic Lupus Erythematosus (SLE)

Summary: this is a prospective, single-arm, open-label, dose-exploration and expansion clinical study of lcar-aio in adult subjects with relapsed/refractory systemic lupus erythematosus.

this is a prospective, single-arm, open-label exploratory clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy profiles of lcar-aio, a chimeric antigen receptor (car) -t cell therapy in subjects with relapsed/refractory systemic lupus erythematosus. patients who meet the eligibility criteria will receive lcar-aio infusion. the study will include the following sequential stages: screening, apheresis, pre-treatment (cell product preparation: lymphodepleting chemotherapy), treatment (lcar aio infusion) and follow-up.

Eligibility criteria:
1. subjects voluntarily participate in clinical research. 2. age 18-65 years. 3. have been diagnosed of sle at least 6 months before screening. 4. at screening, antinuclear antibody, and/or anti-dsdna antibody, and/or anti-sm antibody should be positive. 5. fulfill relapsed/refractory sle conditions. 6. adequate organ function at screening. 7. clinical laboratory values meet criteria at screening. exclusion criteria: 1. active infections such as hepatitis and tuberculosis. 2. other autoimmune diseases. 3. serious underlying diseases such as tumor, uncontrolled diabetes. 4. female subjects who were pregnant, breastfeeding, or planning to become pregnant while participating in this study or within 1 year of receiving lcar-aio treatment. 5. participated in other clinical trials within

Keywords: refractory pulmonary hypertension (pah) recurrent/refractory autoimmune hemolytic anemia (r/r aiha) recurrent/refractory lupus nephritis (r/r ln)
visualization of anti-angiogenic effects with perfusion computed tomography (ctp)

Conditions: Metastatic Colorectal Cancer

Summary: the primary objective of this study is to investigate the anti-angiogenic effect of bevacizumab measured by ctp as a predictive marker for efficacy measured by progression-free survival (pfs) in mcrc patients under first-line bevacizumab-containing, fluoropyrimidine-based chemotherapy

so far, ctp has provided non-invasive imaging of tumor biological response to anti-angiogenic and vascular targeting agents in a number of clinical trials with increasing clinical application. ctp can be examined with a variety of commercially available ce-certified ct scanners and imaging post-processing is possible with commercially available ce-certified software from different vendors, too. in several studies, anti-angiogenic effects have been detected with ctp but further evidence for its clinical validation has to be proven in clinical trials. changes in tumor vasculature measured by ctp will be correlated to the clinical efficacy parameters progression-free survival, overall survival and response rate, thus identifying a group of patients who profit most from the anti-angiogenic treatment.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years, male or female * signed written informed consent * patients with histologically confirmed diagnosis of colorectal cancer with hepatic metastases who are candidates for systemic treatment. * confirmation of metastatic liver disease within one month prior to inclusion in one of the following radiological procedures: * contrast-enhanced spiral computed tomography showing at least one liver nodule ≥ 20 mm in longest diameter according to recist 1.1 criteria * mr imaging of the liver with liver lesions suspicious for metastases * pet computed tomography (pet/ct) with liver lesions suspicious for metastases * patient is eligible and designated for treatment with standard-of-care first-line bevacizumab-containing, fluoropyrimidine-based chemotherapy. * ecog performance status ≤ 2 (see appendix) exclusion criteria: * inability or unwillingness to comply with the participation requirements * history of untreated hyperthyreosis * history of intolerance of or allergy to iodine contrast media according to ctcae v4.03 * calculated creatinine clearance \< 45 ml/min * for fertile women: positive urine pregnancy test or lactation. * known or suspected non-compliance, drug or alcohol abuse * life expectancy of less than 3 months * participation in another interventional trial with an investigational medicinal product (imp) and within 30 days prior to screening

Keywords: perfusion-computed tomography
electronic memory and management aid

Conditions: Subjective Cognitive Complaints; Mild Cognitive Impairment

Summary: this study will evaluate the effectiveness of a personalized, web-based training intervention that was developed to teach use of an electronic memory and management aid (emma) application. the app-based system is designed to support everyday memory, daily activity management and positive health behavior engagement for older adults with subjective cognitive complaints or mild cognitive impairment. the investigators will also evaluate the degree to which a clinician is needed to oversee the uptake and utilization of the emma app during the web-based training intervention.

participants will be randomly assigned to one of two groups, "technical support only" group (t-only group) and "technical + clinician support" group (t+c group). participants will be enrolled in the study for 6 months. participants who pass initial phone screening criteria will participate in a 2-3 hour neurocognitive assessment over zoom to establish baseline cognition, prior to beginning the intervention. participants will also complete questionnaires and a real-world measure assessing daily functioning. after the initial assessment is complete, participants will be given one-month to learn to use the emma app by completing the self-paced intervention via the adaptive, web-based training platform, which includes six lessons. emma device-use will be captured throughout the study by the app itself. a component of the self-paced, web-based intervention involves setting goals related to using the emma app. a clinician will monitor the training data and goals the t+c group participants make and conduct brief problem-solving and goal-refining sessions during the intervention weeks. these sessions are expected to be 10-15 minutes. to keep training on track, the t-only group will receive brief phone check-ins to monitor progression through the web-based intervention. following training, there will no longer be any differences in the treatment of both groups, which will be monitored for an additional three months. immediately following training and at the end of the 3 month monitoring period, all participants will complete the battery of questionnaires and answer a semi-structured phone interview. in addition, at the end of the 3 month follow-up, all participants will again complete the neurocognitive assessment and real-world measure of daily functioning.

Eligibility criteria:
inclusion criteria: * must be age 50 or older * self-reporting subjective cognitive complaints (screening questions) * must be able to read and speak english exclusion criteria: * cannot provide own informed consent * have a known medical, neurological or psychiatric diagnosis that explains current cognitive complaints (e.g., stroke) * cannot complete remote study protocol due to severe vision or hearing difficulties

Keywords: activities of daily living memory electronic aid quality of life health time management
cedata gpge - a patient registry for children and adolescents with inflammatory bowel disease

Conditions: Inflammatory Bowel Disease (IBD)

Summary: cedata gpge collects clinical data of children and adolescents with ibd from paediatric gastroenterology centers in german-speaking countries. data is obtained from participating centers in pseudonymized way via an online platform at the beginning and during followup of the disease. the leading working group of the paediatric gastroenterology society gpge e.v. includes 15 experts in the field who meet twice yearly and coordinate research and quality improvement initiatives.


Eligibility criteria:
inclusion criteria: * inflammatory bowel disease exclusion criteria: * none

Keywords: paediatric crohns disease ulcerative colitis quality improvement patient registry